2017/2951(RSP) | [ParlTrack]

Citation 1 a (new)

- having regard to Article 6 of the Treaty on the Functioning of the European Union,

Amendment 10 #

Recital F a (new)

F a. Whereas, in the period of 2008- 2015, there were 215,000 cases of Vaccine Preventable Diseases (VPDs), excluding influenza, in Europe1a. _________________ 1aCouncil on Foreign Relations (2015), "Vaccine-Preventable Outbreak Maps" 2015.

Amendment 100 #

Paragraph 20

20. Calls on the Member States to punctually provide data on vaccination to the European Centre for Disease Prevention and Control;

Amendment 101 #

Daciana Octavia SÂRBU

Paragraph 20

20. Calls on the Member States to punctually provide data on vaccination coverage to the Commission and the WHO;

Amendment 11 #

Aldo PATRICIELLO

Recital F a (new)

Fa. having regard also to the increasing numbers of intercontinental travellers;

Amendment 12 #

Paragraph 1 a (new)

1 a. Recognises the potential role vaccines can play in reducing the need for antibiotics, thereby helping to limit the spread of Anti-Microbial Resistance (AMR), which should continue to be explored; stresses however that urgently reducing the overuse and misuse of, and unintended exposure to, antibiotics must remain a top priority.

Amendment 13 #

Paragraph 1 a (new)

1 a. Notes that vaccination prevents an estimated 2.5 million deaths each year worldwide and reduces disease-specific treatment costs, including antimicrobial treatments;

Amendment 14 #

Paragraph 2

2. Welcomes that the introduction of the large-scale protective vaccinations in Europe has significantly contributed to the eradication or decline in many infectious diseases; Nnevertheless, is concerned ~~that~~by the ~~above achievements are now gravely~~worrying phenomenon of vaccine hesitancy, and chall~~enged by the worrying phenomenon of vaccine hesitancy~~s for greater transparency in the production of vaccines and in studies into their potential side effects in order to reassure European citizens and put in place the necessary educational measures;

Amendment 15 #

Paragraph 2

2. Welcomes that the introduction of the large-scale protective vaccinations in Europe has significantly contributed to the eradication or decline in many infectious diseases; Nnevertheless, is concerned that the above achievements are now gravely challenged by the worrying phenomenon of vaccine hesitancy; is also concerned at the lack of national recommendations to take account of population ageing, given the particularly vulnerable situation of the elderly;

Amendment 16 #

Paragraph 2

Amendment 17 #

Paragraph 3

3. Points out that ~~Vaccines are safe according to the WHO, as a licensed vaccine is rigorously tested across multipl~~in order to guarantee the safety of a vaccine, it is important that the tests conducted prior to marketing authorisation and the regular analyses conducted after the vaccine phases been placed ofn t~~rials before its use is approved, and regularly reassessed once it is on the market~~he market are carried out by independent researchers whose conflict of interest declarations and conclusions are made public;

Amendment 18 #

Daciana Octavia SÂRBU

Paragraph 3

3. Points out that Vvaccines are ~~safe according to~~rigorously tested through multiple stages of trials before being prequalified by the WHO, a~~s a~~nd/or licensed ~~vaccine is rigorously tested across multiple phases of trials befor~~for use by national authorities; the safety of a licensed vaccine its ~~use is approv~~continuously monitored, and regularly reassessed once it is on the market;

Amendment 19 #

Paragraph 3

3. Points out that Vvaccines are safe according to the WHO, as a licensed vaccine is rigorously tested across multiple phases of trials before its use is approved, and it is regularly reassessed once it is on the market; however, given the discrepancies in the content of vaccine leaflets produced for each Member State, calls on the Member States to conduct independent testing on vaccines authorised in their territory in order to verify whether the information provided by the manufacturers is true, in particular with regard to the composition of the vaccines and any possible adverse effects following vaccination;

Amendment 2 #

Citation 15 a (new)

- having regard to Council Recommendation on seasonal influenza vaccination (2009);

Amendment 20 #

Paragraph 3

3. Points out that Vaccines are safe according to the WHO and the European Medicines Agency (EMA), as a licensed vaccine is rigorously tested across multiple phases of trials before its use is approved, and regularly reassessed once it is on the market;

Amendment 21 #

Paragraph 3

3. Points out that Vvaccines are safe according to the WHO and national health agencies, as a licensed vaccine is rigorously tested across multiple phases of trials before its use is approved, and regularly reassessed once it is on the market;

Amendment 22 #

Paragraph 3 a (new)

3a. Points out that the content of individual leaflets is questionable when it comes to the adverse effects that might occur as a result of vaccination; points out that, in this situation, there is a legitimate need for independent testing to be carried out with the aim of checking discrepancies that have been reported; points out that patients must have full, detailed and accurate information on the vaccines that are available on the market, so that they can choose the right one for their child;

Amendment 23 #

Paragraph 3 a (new)

3a. Proposes that researchers subject to a conflict of interest be excluded from evaluation panels; calls for the confidentiality of the deliberations of the evaluation panel of the European Medicines Agency (EMEA) to be lifted; proposes that the scientific and clinical data which informs the conclusions of the panel, and whose anonymity is guaranteed in advance, be made public;

Amendment 24 #

Paragraph 3 a (new)

3a. Recalls that the European One Health Action Plan against Antimicrobial Resistance (AMR) observes that immunisation through vaccination is a cost-effective public health intervention in efforts to combat antimicrobial resistance1a; _________________ 1a European Commission (29, June 2017), A European One Health Action Plan against Antimicrobial Resistance (AMR), p. 10.

Amendment 25 #

Nikos ANDROULAKIS, Giorgos GRAMMATIKAKIS, Jytte GUTELAND

Paragraph 4

4. Welcomes the active engagement of the Commission on the issue of vaccination and the inclusion of a ~~Joint Action Plan on vaccination, co-funded by the EU Health Programme, in the 2018 Commission Work Programme~~vaccination initiative in the 2018 Commission Work Programme; welcomes the publication of the roadmap for a Council Recommendation on strengthening cooperation against vaccine preventable diseases;

Amendment 26 #

Paragraph 4

4. Welcomes the active engagement of the Commission on the issue of vaccination and the i~~nclus~~mplementation of a Joint Action Plan on vaccination, co- funded by the EU Health Programme~~, in the 2018 Commission Work Programm~~ from Spring 2018, with the participation of 20 Member States; regrets that 8 Member States decided not to participate;

Amendment 27 #

Paragraph 4

4. ~~Welcomes~~Takes note of the active engagement of the Commission on the issue of vaccination and the inclusion of a Joint Action Plan on vaccination, co- funded by the EU Health Programme, in the 2018 Commission Work Programme;

Amendment 28 #

Paragraph 4 a (new)

4 a. Calls on the Commission to elaborate guidelines defining conditions (coverage percentage, epidemic phenomena, etc.) and criteria that can conduct to a compulsory vaccination mechanism, in order to have harmonized guidelines for all Member States.

Amendment 29 #

Paragraph 4 a (new)

4a. Expresses its support for the fact that in its AMR Action Plan the Commission announces that it will provide incentives to increase the uptake of diagnostics, antimicrobial alternatives and vaccines1a; _________________ 1a European Commission (29, June 2017), A European One Health Action Plan against Antimicrobial Resistance (AMR), p. 12.

Amendment 3 #

Jytte GUTELAND, Giorgos GRAMMATIKAKIS, Daciana Octavia SÂRBU, Rory PALMER, Nikos ANDROULAKIS, Pavel POC, Miriam DALLI, Karin KADENBACH, Seb DANCE

Recital B

B. whereas cost of a full vaccines package for one child, even at the lowest global prices, has increased by a factor of 68 from 2001 to 2014; whereas this price increase is unjustifiable and incompatible with the Sustainable Development Goal to ensure healthy lives and promote well- being at all ages;

Amendment 30 #

Paragraph 4 a (new)

4 a. Welcomes the forthcoming launch of a Joint Action co-funded by the EU Health Programme aimed at increasing vaccination coverage;

Amendment 31 #

Paragraph 4 b (new)

4 b. Calls on the Member States and the Commission to reinforce legislative basis for immunization coverage. According to the objective 1 of the European Vaccine Action Plan 2015– 2020, introducing and implementing an appropriate legislative framework is crucial to define national priorities and to concretize a sustainable commitment to immunization.

Amendment 32 #

Paragraph 4 c (new)

4 c. Stresses the importance to create an innovative financing mechanism to allocate funding for immunisation at affordable prices and high-quality supply, identifying any funding gaps thorough MS, in line with the goal 6 and the objective 5 of the European Vaccine Action Plan 2015–2020, in order to achieve financial sustainability of national immunization programmes.

Amendment 33 #

Paragraph 5

5. Strongly supports the Joint Procurement Agreement, which gives Member States and the Commission a framework to jointly procure vaccines, thereby pooling the purchasing power of Member States, ensuring that pandemic vaccines are available in sufficient quantities and avoiding any risk of stocks running out, that access to vaccines is guaranteed, and that all participating Member States are treated equally;

Amendment 34 #

Paragraph 5

5. Strongly supports the Joint Procurement Agreement, which gives Member States and the Commission a framework to jointly procure vaccines, thereby pooling the purchasing power of Member States, ensuring that pandemic vaccines and other vaccines are available in sufficient quantities that access to vaccines is guaranteed, and that all participating Member States are treated equally;

Amendment 35 #

Paragraph 6

6. Welcomes the fact that 24 Member States have signed the Joint Procurement Agreement, meaning that the Agreement covers 447.8 million of the 508.2 million EU citizens; calls on those Member States which have not yet signed the Joint Procurement Agreement to do so to ensure that all EU citizens are covered by the agreement; calls on the Commission to look into the possibility of extending the pooling of purchasing power to all Member States of the European Economic Area and of the Council of Europe;

Amendment 36 #

Paragraph 7

7. Recalls the importance of transparency in building and maintaining public trust in medicines; recommends in that vein the importance a) of commissioning independent trials and studies of all vaccinations, and b) publication of the results of those trials and studies;

Amendment 37 #

Paragraph 7

7. Recalls the importance of transparency in building and maintaining public trust in medicines, including vaccines, given the growing phenomenon of vaccine hesitancy in several Member States;

Amendment 38 #

Paragraph 7 a (new)

7 a. Whereas in order to ensure the highest protection of human health and to reduce vaccine hesitancy, the chances of any negative health effects resulting from, or perceived to result from vaccinations, however rare, need to be reduced as much as possible; Calls on Member States to consider the introduction of a preventive and precautionary pre-vaccination test, at least for some fragile and vulnerable categories of patients, which takes into consideration, inter alia, their age, intolerances and health condition, in order to help prevent any adverse health reactions and to therefore also counter vaccine hesitancy.

Amendment 39 #

Paragraph 8

8. Recalls the importance of the Clinical Trials Regulation in stimulating and facilitating research into new vaccinations and ensuring transparency of results of clinical trials; calls on the Commission and the European Medicines Agency to implement the Clinical Trials Regulation without further delay and to promote publication of the results, in order to inform the public in the Member States and provide reassurance with respect to any concerns they may have;

Amendment 4 #

Recital C

C. Wwhereas within the EU/EEA, countries vary considerably with respect to recommended vaccines and organisation of health services, given that protection and improvement of human health are matters for the Member States and cannot be subject to legally binding acts outside the national framework;

Amendment 40 #

Rory PALMER, Elena GENTILE, Lynn BOYLAN, Deirdre CLUNE, Seb DANCE

Paragraph 8

8. Recalls the importance of the Clinical Trials Regulation in stimulating and facilitating research into new vaccinations and ensuring transparency of results of clinical trials; calls on the Commission and the European Medicines Agency to implement the Clinical Trials Regulation without further delay; in particular through setting up the European Portal and Database (EUPD) whose implementation has seen significant delays of over two years;

Amendment 41 #

Rory PALMER, Elena GENTILE, Lynn BOYLAN, Deirdre CLUNE, Seb DANCE

Paragraph 8 – subparagraph 1 (new)

Further calls upon all parties involved to ensure that the current process of relocating the EMA away from London does not cause any additional disruption or delays to the work of the Agency;

Amendment 42 #

Paragraph 9

9. Calls on Member States to ensure that all healthcare workers are sufficiently vaccinated themselves; calls on the Commission to address the vaccination rates of healthcare workers in the ~~Joint Action Pla~~Council Recommendation;

Amendment 43 #

Nikos ANDROULAKIS, Giorgos GRAMMATIKAKIS, Jytte GUTELAND

Paragraph 9

9. Calls on Member States to ensure that all healthcare workers are sufficiently vaccinated themselves; calls on the Commission to ~~address~~coordinate the vaccination rates of healthcare workers in the Joint Action Plan;

Amendment 44 #

Paragraph 9 a (new)

9 a. Believes that the initiative of the European Commission regarding the Strengthened cooperation against vaccine preventable diseases, due to be presented the second quarter of 2018 in the form of Council Recommendations on supporting Member States in implementing vaccination programmes, reducing vaccine hesitancy strengthening the supply of vaccines and overall improving vaccination coverage, is a good step; Calls the European Commission and the Council to take into account the position of the European Parliament in the drafting of the recommendations;

Amendment 45 #

Paragraph 10

10. Notes with concern that epidemiological data on the current situation of vaccination in the Member States shows important gaps in the uptake of vaccines and insufficient vaccination coverage rates necessary to ensure adequate protection; is concerned that widespread vaccine hesitancy has become a worrying phenomenon due to the range of health-related consequences it causes in the Member States; is alarmed at the spread of false information on the internet, which is contributing to public hesitancy;

Amendment 46 #

Paragraph 10

10. Notes with concern that epidemiological data on the current situation of vaccination in the Member States shows important gaps in the uacceptaknce of vaccines and insufficient vaccination coverage rates necessary to ensure adequate protection; is concerned that growing and widespread vaccine hesitancy has become a worrying phenomenon due to the range of health- related consequences it causes in the Member States;

Amendment 47 #

Paragraph 10 – subparagraph 1 (new)

Calls on the Member States, given the usefulness of vaccination as a preventive tool, to ensure that vaccine coverage is extended beyond early childhood and that all population groups can be included in a lifelong vaccination approach;

Amendment 48 #

Paragraph 10 a (new)

10 a. Underlines that the waning of public confidence in vaccination worldwide is a cause for concern and a major challenge for public health experts; notes that Europe is currently facing avoidable measles outbreaks in a number of countries owing to vaccine hesitancy; calls on the Commission to keep reinforcing its support to national vaccination efforts to increase coverage;

Amendment 49 #

Paragraph 10 a (new)

10a. Stresses that increased transparency in the process of evaluating vaccines and their adjuvants and the funding of independent research programmes on their possible side-effects would contribute to restoring confidence in vaccination;

Amendment 5 #

Recital D a (new)

Da. whereas, in accordance with Article 6 of the Treaty on the Functioning of the European Union, the protection and improvement of human health are supporting competences, in respect of which the Commission is authorised to act only to support, coordinate or supplement the actions of the Member States, and whereas, therefore, legally binding acts of the European Union cannot require harmonisation of the laws and regulations of the European States,

Amendment 50 #

Paragraph 10 a (new)

10 a. Calls on the Commission and Members States to strengthen the infrastructure for data collection to track infectious disease patterns and the real-life impact of vaccines to support the delivery of immunisation programmes.

Amendment 51 #

György HÖLVÉNYI

Paragraph 11

11. Is concerned by the wide variation in the vaccines that are recommended, provided and/or mandated by different Member States; is concerned that this variation in vaccination coverage exacerbates health inequalities between Member States and undermines efforts to reduce and eliminate preventable diseases;deleted

Amendment 52 #

Paragraph 11

11. Is concerned by the wide variation in the vaccines that are recommended, provided and/or mandated by different Member States and by the insufficient financial support for vaccination provided by the social security authorities in a number of Member States; is concerned that this variation in vaccination coverage exacerbates health inequalities between Member States and undermines efforts to reduce and eliminate preventable diseases;

Amendment 53 #

Paragraph 12

12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps ~~against the spread of such misinformation and to further develop awareness and information campaigns~~to restore confidence in vaccines and to enhance education and listening, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage;

Amendment 54 #

Paragraph 12

12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps ~~against the spread of such misinformation and~~ to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage, and thus to prevent such misleading information from proving effective and being disseminated;

Amendment 55 #

Paragraph 12

12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to ~~take effective steps against the spread of such misinformation~~counter the spread of such misinformation by publishing the results of any and all independent studies verifying the effectiveness of the most controversial vaccines, and to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage;

Amendment 56 #

Paragraph 12

12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; points out that vaccination hesitancy has also been fuelled by media sensationalism and by poor journalism that gives "false balance" in which, for example, anecdotal stories are presented as the counter balance for strong scientific evidence; calls on Member States and the Commission to take effective steps against the spread of such misinformation and to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage;

Amendment 57 #

Paragraph 12

12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps against the spread of such misinformation and to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage, while nevertheless upholding freedom of expression, as education must take precedence over censorship, the perverse effect of which is to consolidate unfounded beliefs;

Amendment 58 #

Jytte GUTELAND, Giorgos GRAMMATIKAKIS, Daciana Octavia SÂRBU, Rory PALMER, Nikos ANDROULAKIS, Pavel POC, Miriam DALLI, Karin KADENBACH, Seb DANCE

Paragraph 12 a (new)

12 a. Emphasises the need for inclusive, factual and science-based information to citizens; calls on the Commission and Member States to facilitate dialogue with stakeholders from civil society, grass root movements, academia, media and national health authorities in order to combat unreliable, misleading and unscientific information on vaccination;

Amendment 59 #

Paragraph 12 a (new)

12 a. Notes that future EU incentives on vaccination could tackle vaccine hesitancy in the context of the growing impact of digitalisation and social media, using vaccines as the case study for combating fake news in the EU;

Amendment 6 #

Recital E a (new)

E a. Whereas, according to a global survey undertaken by the Vaccine Confidence Project, the European region has the highest negative responses in terms of perception of the importance of vaccines and their safety and effectiveness, leading to the highest degree of vaccine hesitancy in the population1a. _________________ 1aLarson, Heidi J. et al. (2016). The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016; Volume 12, 295 – 301.

Amendment 60 #

Paragraph 13

13. Is concerned about the high prices of some life-saving vaccines; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicineslimited budget allocated specifically to vaccination in some Member States; stresses that vaccination is one of the most efficient and cost-effective public health interventions for healthcare systems in the long term;

Amendment 61 #

Paragraph 13

13. Is concerned about the high prices of ~~some~~many life-saving vaccines and condemns this profiteering from misery; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;

Amendment 62 #

Paragraph 13

13. Is concerned about the high prices and large differences in price of some life- saving vaccines within and outside the EU; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines; further calls on the Commission to improve transparency in the cost of research, development and production of vaccines;

Amendment 63 #

Paragraph 13

13. Is concerned about the alarmingly high prices of some life-saving vaccines~~; calls on~~, for which there is still too often no satisfactory explanation and justification, for example based on R&D costs; urges the Commission and the Member States as soon as possible to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;

Amendment 64 #

Jytte GUTELAND, Giorgos GRAMMATIKAKIS, Daciana Octavia SÂRBU, Rory PALMER, Nikos ANDROULAKIS, Pavel POC, Miriam DALLI, Karin KADENBACH, Seb DANCE

Paragraph 13

13. Is concerned about the high prices of some life-saving vaccines and that this risks further exacerbating existing health inequalities in society; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;

Amendment 65 #

Nikos ANDROULAKIS, Giorgos GRAMMATIKAKIS

Paragraph 13

13. Is concerned about the high prices ~~of some~~set by some pharmaceutical laboratories for life-saving vaccines; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;

Amendment 66 #

Paragraph 13

Amendment 67 #

Paragraph 14

14. Is concerned that high vaccine prices disproportionately affect low and middle income countries, including countries that are losing donor support through Gavi, the Vaccine Alliance; calls on the Commission and Member States to take measures to help facilitate access to vaccines in those countries; calls, therefore, on social security institutions to step up their demands in negotiations with pharmaceutical companies on the setting of vaccine prices;

Amendment 68 #

Paragraph 14

Amendment 69 #

Paragraph 14 a (new)

14 a. Calls on the Commission to ensure that any development of new vaccines which receives public funding through the EU delivers more affordable end products by applying access conditions such as price ceilings or equitable licensing conditions;

Amendment 7 #

Recital E a (new)

Ea. whereas mass vaccination can eradicate a number of diseases and thus avoid epidemics which could cause many deaths;

Amendment 70 #

Paragraph 15

15. Welcomes the encouraging progress made in the fight against cervical cancer thanks to vaccination programmes against the HPV virus; calls on the Member States to further develop these programmes and explore ways to increase coverage rates and prevent other forms of cancer, for example by including boys in vaccination programmes;deleted

Amendment 71 #

Paragraph 15

15. ~~Welcom~~Stresses the ~~encouraging progress made in~~importance of the fight against cervical cancer ~~thanks to~~; draws attention, nevertheless, to the potential side-effects of vaccination ~~programmes~~ against the HPV virus; calls on the Member States to further develop the~~se programmes and explore ways to increase coverage rates and prevent other forms of cancer, for example by including boys in vaccination programme~~ transparency of these vaccination programmes and prevent other forms of cancer, including male cancers;

Amendment 72 #

Paragraph 15

15. Welcomes the encouraging progress made in the fight against ~~cervical~~HPV diseases and cancers thanks to vaccination programmes against the HPV virus; calls on the Member States to further develop these programmes and explore ways to increase coverage rates and prevent other forms of cancer, for example by including boys in vaccination programmes;

Amendment 73 #

Jytte GUTELAND, Giorgos GRAMMATIKAKIS, Rory PALMER, Nikos ANDROULAKIS, Pavel POC, Miriam DALLI, Karin KADENBACH, Seb DANCE

Paragraph 15 a (new)

15 a. Deplores the persisting inequalities between women and men in participation in clinical trials, which may hinder medicinal research and the development of vaccines for diseases where a majority of patients are women; calls on the Commission and Member States to take measures to eliminate this discriminating gender gap;

Amendment 74 #

Paragraph 16

16. Believes providing vaccination services for migrants and refugees entering EU countries is critical since mass vaccination can eradicate a number of diseases and thus avoid epidemics which could cause many deaths; calls on the Commission and Member States to map what concrete vaccination activities are being implemented for migrants and refugees entering EU countries and work to address the identified gaps;

Amendment 75 #

Paragraph 16

16. Believes providing vaccination screening and vaccination services for migrants and refugees entering EU countries is critical; calls on the Commission and Member States to map what concrete vaccination activities are being implemented for migrants and refugees entering EU countries and work energetically to address the identified gaps;

Amendment 76 #

Paragraph 16

16. Believes providing vaccination services for migrants and refugees ~~enter~~ing EU countries is critical; calls on the Commission and Member States to map what concrete vaccination activities are being implemented for migrants and refugees ~~enter~~ing EU countries and work to address the identified gaps;

Amendment 77 #

Paragraph 16 a (new)

16 a. Is concerned by vaccine shortages and calls on the Commission and the Member States to develop solutions to increase vaccine supply and availability, including arrangements for stockpiling vaccines;

Amendment 78 #

Paragraph 17

17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians, nurses and pharmacists who provide vaccinations underlining their obligations, ~~including~~both moral and ethical, to protect public health by providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision;

Amendment 79 #

Paragraph 17

17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among ~~physician~~health-care professionals who provide vaccinations underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision;

Amendment 8 #

Recital F a (new)

Fa. whereas, on the basis of the 'One Health' approach, various Member States regard vaccination of agricultural and domestic animals as an important measure both to prevent outbreaks of cross-border animal diseases and to limit the risk of further contagion, and have introduced it, including against infections by Coxiella burnettii and other bacterial and viral diseases which also present public health risks;

Amendment 80 #

Paragraph 17

17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about compulsory and recommended vaccines so that they can make an informed decision;

Amendment 81 #

Paragraph 17

17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision; calls for disciplinary accountability to be introduced for doctors who fail to provide such information;

Amendment 82 #

Paragraph 17

17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations, underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision;

Amendment 83 #

Paragraph 17 a (new)

17a. Points out that doctors often fail to provide all the information on the benefits of vaccines and on adverse effects that might occur after administration of one vaccine or another; points out that in this situation there is a need for doctors also to inform parents about possible adverse effects, and for sanctions to be imposed where doctors fail to comply with that obligation;

Amendment 84 #

Paragraph 17 a (new)

17 a. Points out that health-care professionals are the cornerstone of public acceptance of vaccination and their recommendations are consistently cited as a primary reason for vaccination1a. _________________ 1aLeask J, Kinnersley P, Jackson C, Cheater F, Bedford H, Rowles G. Communicating with parents about vaccination: a framework for health professionals. BMC Pediatr 2012;12:154.

Amendment 85 #

Paragraph 18

18. Calls on the Commission and the Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments, including priority and region-specific actions, ~~and taking into account the varying circumstances and specific challenges faced by the Member States;~~in line with the European Vaccine Action plan 2015- 2020.

Amendment 86 #

Paragraph 18

18. Calls on the ~~Commission and the~~ Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments, including priority and region-specific actions, and taking into account the varying circumstances and specific challenges faced by the Member States;

Amendment 87 #

Daciana Octavia SÂRBU

Paragraph 18

18. Calls on the Commission and the Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments to immunization as a priority public health measure, including priority and region-specific actions, and taking into account the varying circumstances and specific challenges faced by the Member States;

Amendment 88 #

Paragraph 19

19. Calls on the Commission to facilitate a more harmonised and better aligned schedule for vaccination across the EU, to share best practice, ensure even coverage across Europe ~~and~~, reduce health inequalities and help to increase trust and confidence in vaccination programmes and vaccines;

Amendment 89 #

Paragraph 19

19. Calls on the Commission to ~~facilit~~coordinate a more harmonised schedule for vaccination across the EU, to s~~hare~~upplement best practice, between countries, to support Member States' action to ensure even coverage across Europe and reduce health inequalities;

Amendment 9 #

Recital F a (new)

Fa. whereas in some Member States public mistrust of vaccines is growing significantly, leading to a worrying refusal to vaccinate;

Amendment 90 #

Paragraph 19

19. Calls on the Commission to facilitate a more harmonised schedule for vaccination across the EU, to share best practice, to explore with Member States options to establish an EU platform for the monitoring of the safety and effectiveness of vaccines, to ensure even coverage across Europe and reduce health inequalities;

Amendment 91 #

Paragraph 19

19. Calls on the Commission to facilitate a more harmonised schedule for vaccination across the EU, to share best practice, ensure even coverage across Europe and reduce costs and health inequalities;

Amendment 92 #

Paragraph 19 – subparagraph 1 (new)

Calls on the Commission to establish targeted vaccination initiatives, such as a 'European influenza vaccination day’, which could be used each year to launch the vaccination campaign in line with the 75% coverage target laid down in the Council recommendations on seasonal influenza;

Amendment 93 #

Paragraph 19 a (new)

19a. Calls on the Member States to introduce voluntary vaccination, ensuring that all those who are prepared to be vaccinated have access to free vaccines, and, in countries in which vaccination is compulsory, to set up funds to compensate those who experience adverse effects following vaccination; points out that in countries like Poland, where vaccination is compulsory, and additionally the subject of coercion on the part of the state, there is no compensation fund for those who experience adverse effects following vaccination; proposes that funds be introduced in all Member States to compensate those who experience adverse effects following vaccination;

Amendment 94 #

Paragraph 19 a (new)

19a. Calls on the Commission and Member States to adopt concrete 'One Health' measures to increase vaccination rates in both humans and, where necessary, animals by means of financial and policy incentives, and thus to combat infectious diseases and also antibiotic resistance more cost-effectively, inter alia in the context of the future Common Agricultural Policy beyond 2020;

Amendment 95 #

Paragraph 19 b (new)

19b. Calls on the Member States to set up a targeted compensation fund to provide financial support and rehabilitation for people who have experienced complications following vaccination; points out that forced vaccination is a breach of the Convention for the Protection of Human Rights and Fundamental Freedoms; points out that the European Court of Human Rights, for example, has taken such a position with regard to compulsory vaccination, stating that coercion is a breach of Article 8 of the Convention for the Protection of Human Rights and Fundamental Freedoms: ‘The Commission recalls that private life [...] includes a person’s physical and psychological integrity’ (No 32647/96, Decision of 1.7.1998, DR 94, p. 91-93); points out that the Court examined an application on the basis of Article 8 of the Convention, which stipulates: ‘1. Everyone has the right to respect for his private and family life, his home and his correspondence. 2. There shall be no interference by a public authority with the exercise of this right except such as is in accordance with the law and is necessary in a democratic society in the interests of national security, public safety or the economic well-being of the country, for the prevention of disorder or crime, for the protection of health or morals, or for the protection of the rights and freedoms of others’; points out that the Court considers that compulsory vaccination, as compulsory medical intervention, constitutes interference with the right to respect for private life guaranteed by Article 8(1);

Amendment 96 #

Paragraph 19 c (new)

19c. Calls on the Member States to monitor the adverse effects caused by vaccines, to keep registers of the adverse effects of vaccinations, to bring in judicial oversight of those records, and to take action to minimise or eliminate adverse effects caused by vaccines;

Amendment 97 #

Paragraph 19 d (new)

19d. Points out that although a register of the adverse effects of vaccinations is kept in Poland, it does not always reflect the actual situation; points out that the body whose job it is to keep the register has conflicting responsibilities, in that it is also responsible for ensuring that vaccination rates remain sufficiently high; points out that this justifies the need for registers of adverse effects to be monitored by independent courts that are not involved in ruling on the cases concerned;

Amendment 98 #

Paragraph 20

20. Calls on the Member States to punctually provide data on vaccination; Moreover, member States have to monitor and report every year to the regional offices all progresses made, remaining challenges and updated actions to reach the national immunizations targets.

Amendment 99 #